MBX Biosciences Highlights Sustained Calcium Control In Rare Disease - MBX Biosciences (NASDAQ:MBX)

MBX Biosciences reported one-year canvuparatide data showing sustained calcium control and progress toward a Phase 3 trial.

Raccontata dabenzinga.com